SecurityWHLR / Wheeler Real Estate Investment Trust, Inc.
IndustryReal Estate Investment Trusts
Institutional Buyers9
Opened Positions2
Related WHIR / Wheeler Real Estate Investment Trust, Inc.
WHLRD / Wheeler Real Estate Investment Trust, Inc., 8.75% Series D Cumulative Convertible Preferred Stock
WHLRP / Wheeler Real Estate Investment Trust, Inc., 9.00% Series B Cumulative Convertible Preferred Stock
WHLRW / Wheeler Real Estate Investment Trust, Inc., Warrants

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in WHLR / Wheeler Real Estate Investment Trust, Inc. include Susquehanna International Group, Llp, and Bay Colony Advisory Group, Inc D/b/a Bay Colony Advisors.

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Prev Shares Shares Change
(Percent)
Prev Value
(x$1000)
Current Value (x$1000) Change
(Percent)
2018‑08‑14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 11,352 46
2018‑08‑14 13F-HR Tower Research Capital LLC (TRC) 211 968 358.77 1 4 300.00
2018‑08‑09 13F-HR Bay Colony Advisory Group, Inc D/b/a Bay Colony Advisors 660 3
2018‑08‑06 13F-HR Bank of New York Mellon Corp 14,820 28,673 93.48 53 116 118.87
2018‑08‑14 13F-HR DIAM Co., Ltd. 16,501 20,207 22.46 59 79 33.90
2018‑08‑15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 480 486 1.25 1,718 1,963 14.26
2018‑08‑09 13F-HR BlackRock Inc. 69,056 74,002 7.16 247 300 21.46
2018‑08‑14 13F-HR ROYAL BANK OF CANADA 0 187 0 1
2017‑02‑10 13F-HR BlackRock Fund Advisors 157,894 160,538 1.67 276 273 -1.09

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 963025101